TY - JOUR
T1 - Biopolymer-Capped Pyrazinamide-Loaded Colloidosomes : In Vitro Characterization and Bioavailability Studies
AU - Singh, Avi
AU - Das, Sabya Sachi
AU - Ruokolainen, Janne
AU - Kesari, Kavindra Kumar
AU - Singh, Sandeep Kumar
N1 - Funding Information:
A.S. acknowledges the financial assistance provided by the Department of Science and Technology, Government of India, under Inspire Programme (IF: 180432). The authors acknowledge the central instrument facility of the Birla Institute of Technology. The graphical abstract has been created using Biorender.
Publisher Copyright:
© 2023 The Authors. Published by American Chemical Society.
PY - 2023/7/6
Y1 - 2023/7/6
N2 - This study aimed to prepare colloidosome particles loaded with pyrazinamide (PZA). These drug-loaded colloidosomes were prepared using an in situ gelation technique using a central composite design with a shell made of calcium carbonate (CaCO3) particles. Optimal amounts of 150 mg of CaCO3, sodium alginate (2%), and 400 mg of poly(3-hydroxybutyrate-co-3-hydroxy valerate) (PHBV) concentration resulted in the maximum drug loading and efficient release profile. Field emission scanning electron microscopy results showed spherical porous particles with a good coating of the PHBV polymer. Additionally, Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), thermogravimetric and differential thermal analysis (TGA-DTA), and X-ray diffraction (XRD) analysis showed good compatibility between the drug and excipients. The pharmacokinetic studies demonstrated that the drug-loaded colloidosomes resulted in 4.26 times higher plasma drug concentrations with Cmax values of 32.386 ± 2.744 mcg/mL (PZA solution) and 115.868 ± 53.581 mcg/mL (PZA-loaded colloidosomes) and AUC0-t values of 61.24 mcg-h/mL (PZA solution) and 260.9 mcg-h/mL (PZA-loaded colloidosomes), indicating that colloidosomes have the potential to be effective drug carriers for delivering PZA to the target site.
AB - This study aimed to prepare colloidosome particles loaded with pyrazinamide (PZA). These drug-loaded colloidosomes were prepared using an in situ gelation technique using a central composite design with a shell made of calcium carbonate (CaCO3) particles. Optimal amounts of 150 mg of CaCO3, sodium alginate (2%), and 400 mg of poly(3-hydroxybutyrate-co-3-hydroxy valerate) (PHBV) concentration resulted in the maximum drug loading and efficient release profile. Field emission scanning electron microscopy results showed spherical porous particles with a good coating of the PHBV polymer. Additionally, Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), thermogravimetric and differential thermal analysis (TGA-DTA), and X-ray diffraction (XRD) analysis showed good compatibility between the drug and excipients. The pharmacokinetic studies demonstrated that the drug-loaded colloidosomes resulted in 4.26 times higher plasma drug concentrations with Cmax values of 32.386 ± 2.744 mcg/mL (PZA solution) and 115.868 ± 53.581 mcg/mL (PZA-loaded colloidosomes) and AUC0-t values of 61.24 mcg-h/mL (PZA solution) and 260.9 mcg-h/mL (PZA-loaded colloidosomes), indicating that colloidosomes have the potential to be effective drug carriers for delivering PZA to the target site.
UR - http://www.scopus.com/inward/record.url?scp=85164907637&partnerID=8YFLogxK
U2 - 10.1021/acsomega.3c03135
DO - 10.1021/acsomega.3c03135
M3 - Article
AN - SCOPUS:85164907637
SN - 2470-1343
VL - 8
SP - 25515
EP - 25524
JO - ACS Omega
JF - ACS Omega
IS - 28
ER -